A PHP Error was encountered

Severity: Warning

Message: file_get_contents(https://...@gmail.com&api_key=61f08fa0b96a73de8c900d749fcb997acc09): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests

Filename: helpers/my_audit_helper.php

Line Number: 143

Backtrace:

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 143
Function: file_get_contents

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 209
Function: simplexml_load_file_from_url

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 994
Function: getPubMedXML

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3134
Function: GetPubMedArticleOutput_2016

File: /var/www/html/application/controllers/Detail.php
Line: 574
Function: pubMedSearch_Global

File: /var/www/html/application/controllers/Detail.php
Line: 488
Function: pubMedGetRelatedKeyword

File: /var/www/html/index.php
Line: 316
Function: require_once

Artificial intelligence-assisted digital pathology for non-alcoholic steatohepatitis: current status and future directions. | LitMetric

AI Article Synopsis

  • - The increasing prevalence of non-alcoholic steatohepatitis (NASH) is a major healthcare issue, with no current approved treatments available, highlighting the urgent need for effective drug development methods.
  • - Histological analysis of liver biopsies for NASH trials faces challenges like sample variability and scoring inconsistencies, making it difficult to assess treatment efficacy accurately.
  • - Digital pathology (DP) and artificial intelligence (AI) are being explored to enhance the analysis of NASH histology, aiming to improve accuracy and reproducibility in clinical trials, which is essential for advancing safe and effective therapies.

Article Abstract

The worldwide prevalence of non-alcoholic steatohepatitis (NASH) is increasing, causing a significant medical burden, but no approved therapeutics are currently available. NASH drug development requires histological analysis of liver biopsies by expert pathologists for trial enrolment and efficacy assessment, which can be hindered by multiple issues including sample heterogeneity, inter-reader and intra-reader variability, and ordinal scoring systems. Consequently, there is a high unmet need for accurate, reproducible, quantitative, and automated methods to assist pathologists with histological analysis to improve the precision around treatment and efficacy assessment. Digital pathology (DP) workflows in combination with artificial intelligence (AI) have been established in other areas of medicine and are being actively investigated in NASH to assist pathologists in the evaluation and scoring of NASH histology. DP/AI models can be used to automatically detect, localise, quantify, and score histological parameters and have the potential to reduce the impact of scoring variability in NASH clinical trials. This narrative review provides an overview of DP/AI tools in development for NASH, highlights key regulatory considerations, and discusses how these advances may impact the future of NASH clinical management and drug development. This should be a high priority in the NASH field, particularly to improve the development of safe and effective therapeutics.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2023.10.015DOI Listing

Publication Analysis

Top Keywords

digital pathology
8
non-alcoholic steatohepatitis
8
nash
8
drug development
8
histological analysis
8
efficacy assessment
8
assist pathologists
8
nash clinical
8
artificial intelligence-assisted
4
intelligence-assisted digital
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!